167 related articles for article (PubMed ID: 26428728)
21. 18F-FDG PET in sarcoidosis: an observational study in 12 patients treated with infliximab.
Keijsers RG; Verzijlbergen JF; van Diepen DM; van den Bosch JM; Grutters JC
Sarcoidosis Vasc Diffuse Lung Dis; 2008 Dec; 25(2):143-9. PubMed ID: 19382534
[TBL] [Abstract][Full Text] [Related]
22. Frequency of acute worsening events in fibrotic pulmonary sarcoidosis patients.
Baughman RP; Lower EE
Respir Med; 2013 Dec; 107(12):2009-13. PubMed ID: 24211131
[TBL] [Abstract][Full Text] [Related]
23. Inhibitors of tumor necrosis factor (TNF) in sarcoidosis: who, what, and how to use them.
Baughman RP; Lower EE; Drent M
Sarcoidosis Vasc Diffuse Lung Dis; 2008 Dec; 25(2):76-89. PubMed ID: 19382527
[TBL] [Abstract][Full Text] [Related]
24. Beneficial effect of infliximab on refractory sarcoidosis.
Ørum M; Hilberg O; Krag S; Bendstrup E
Dan Med J; 2012 Dec; 59(12):A4535. PubMed ID: 23290282
[TBL] [Abstract][Full Text] [Related]
25. Refractory chronic cutaneous sarcoidosis responsive to dose escalation of TNF-alpha antagonists.
Thielen AM; Barde C; Saurat JH; Laffitte E
Dermatology; 2009; 219(1):59-62. PubMed ID: 19468200
[TBL] [Abstract][Full Text] [Related]
26. Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement.
Baughman RP; Drent M; Kavuru M; Judson MA; Costabel U; du Bois R; Albera C; Brutsche M; Davis G; Donohue JF; Müller-Quernheim J; Schlenker-Herceg R; Flavin S; Lo KH; Oemar B; Barnathan ES;
Am J Respir Crit Care Med; 2006 Oct; 174(7):795-802. PubMed ID: 16840744
[TBL] [Abstract][Full Text] [Related]
27. Inflammatory profile and response to anti-tumor necrosis factor therapy in patients with chronic pulmonary sarcoidosis.
Loza MJ; Brodmerkel C; Du Bois RM; Judson MA; Costabel U; Drent M; Kavuru M; Flavin S; Lo KH; Barnathan ES; Baughman RP
Clin Vaccine Immunol; 2011 Jun; 18(6):931-9. PubMed ID: 21508170
[TBL] [Abstract][Full Text] [Related]
28. Real-world Effectiveness of Biologic Disease-modifying Antirheumatic Drugs for the Treatment of Rheumatoid Arthritis After Etanercept Discontinuation in the United Kingdom, France, and Germany.
Li N; Betts KA; Messali AJ; Skup M; Garg V
Clin Ther; 2017 Aug; 39(8):1618-1627. PubMed ID: 28729087
[TBL] [Abstract][Full Text] [Related]
29. Established and experimental medical therapy of pulmonary sarcoidosis.
Baughman RP; Nunes H; Sweiss NJ; Lower EE
Eur Respir J; 2013 Jun; 41(6):1424-38. PubMed ID: 23397302
[TBL] [Abstract][Full Text] [Related]
30. Adalimumab efficacy in enteropathic spondyloarthritis: A 12-mo observational multidisciplinary study.
Luchetti MM; Benfaremo D; Ciccia F; Bolognini L; Ciferri M; Farinelli A; Rossini M; Mosca P; Triolo G; Gabrielli A
World J Gastroenterol; 2017 Oct; 23(39):7139-7149. PubMed ID: 29093622
[TBL] [Abstract][Full Text] [Related]
31. Head and neck sarcoidosis, from wait and see to tumor necrosis factor alpha therapy: a pilot study.
Knopf A; Lahmer T; Chaker A; Stark T; Hofauer B; Pickhard A; Thürmel K; Bas M
Head Neck; 2013 May; 35(5):715-9. PubMed ID: 22730039
[TBL] [Abstract][Full Text] [Related]
32. Combination therapy of cyclosporine and anti-tumor necrosis factor α in psoriasis: a case series of 10 patients.
Cohen Barak E; Kerner M; Rozenman D; Ziv M
Dermatol Ther; 2015; 28(3):126-30. PubMed ID: 25640261
[TBL] [Abstract][Full Text] [Related]
33. Efficacy, safety and cost per responder of biologics in the treatment of non-radiographic axial spondyloarthritis.
Olivieri I; Fanizza C; Gilio M; Ravasio R
Clin Exp Rheumatol; 2016; 34(5):935-940. PubMed ID: 27385374
[TBL] [Abstract][Full Text] [Related]
34. Predictive value of C-reactive protein and clinically relevant baseline variables in sarcoidosis.
McDonnell MJ; Saleem MI; Wall D; Gilmartin JJ; Rutherford RM; O'Regan A
Sarcoidosis Vasc Diffuse Lung Dis; 2016 Dec; 33(4):331-340. PubMed ID: 28079845
[TBL] [Abstract][Full Text] [Related]
35. [Dynamics of clinical, X-ray and functional data during treatment of patients with sarcoidosis].
Vizel IY; Vizel AA
Klin Med (Mosk); 2017; 95(1):60-5. PubMed ID: 30299068
[TBL] [Abstract][Full Text] [Related]
36. Infliximab for treating sarcoidosis patients, Portuguese experience.
Aguiar M; Marçal N; Mendes AC; Bugalho de Almeida A
Rev Port Pneumol; 2011; 17(2):85-93. PubMed ID: 21477572
[TBL] [Abstract][Full Text] [Related]
37. Comparative Effectiveness and Safety of Anti-Tumor Necrosis Factor Agents in Biologic-Naive Patients With Crohn's Disease.
Singh S; Heien HC; Sangaralingham LR; Schilz SR; Kappelman MD; Shah ND; Loftus EV
Clin Gastroenterol Hepatol; 2016 Aug; 14(8):1120-1129.e6. PubMed ID: 27058635
[TBL] [Abstract][Full Text] [Related]
38. The impact of prior biologic therapy on adalimumab response in patients with rheumatoid arthritis.
Feuchtenberger M; Kleinert S; Scharbatke EC; Gnann H; Behrens F; Wittig BM; Greger G; Tony HP
Clin Exp Rheumatol; 2015; 33(3):321-9. PubMed ID: 25897681
[TBL] [Abstract][Full Text] [Related]
39. Lung sarcoidosis induced by TNF antagonists in rheumatoid arthritis: a case presentation and a literature review.
Gifre L; Ruiz-Esquide V; Xaubet A; Gómez-Puerta JA; Hernández MV; Sanmartí R
Arch Bronconeumol; 2011 Apr; 47(4):208-12. PubMed ID: 20638761
[TBL] [Abstract][Full Text] [Related]
40. Pulmonary sarcoidosis.
Baughman RP
Clin Chest Med; 2004 Sep; 25(3):521-30, vi. PubMed ID: 15331189
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
